GSK to Acquire Celiac-Focused Sitari PharmaceuticalsAcquisitions, Business, Celiac Disease, Clinical Data, Deals, Small Molecules, Transglutaminase 2 (TG2), VenturesGlaxoSmithKline will acquire San Diego-based Sitari Pharmaceuticals and the company’s transglutaminase 2 small molecule program for celiac disease. Read more September 11, 2019/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2019-09-11 12:27:262019-09-11 13:25:24GSK to Acquire Celiac-Focused Sitari Pharmaceuticals